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Endometrial Cancer

Dr. Burke says these are Lhe Lypes
of
cases
that are resolved in multi(Continued from page 1)
disciplinary planning conferences,
where many physicians consul't on
single cases. "These are the cases that
''That is a very fortunate set of
generate a lot of discussion," be says.
circumstances for women who fit
After one or more plans are formuthat pattern,» Dr. Burke said.
lated, options are presented co the
For the patients who do not fit
patient, and a choice is made in
that pattern-those who have grade
patient-physician consultation.
2 or 3 less differentiated cancers or
Dr. Burke says that total abdominal
any of the variant cell types (papillary
hysterectomy and oophorectomy with
serous or clear cell cancers, for
pelvic and para-aortic node sampling
example)-more extensive staging
for endometrial cancer is the most
evaluation is required at surgery,
commonly performed gynecologic
These cases represent about oneoncology procedure, and it was the
third of all patients.
first care path co be plotted by M. D.
"For patiellts who have grade 2 or
Anderson's Practice Outcomes
grade 3 less differentiated cancers or
Program.
any of the variant cell types who are
With implementation of the path,
at risk for spread of disease our.side
median values oflength of hospital
the uterus, the usual factors, such
stay fell from six to four days and of
as depth of invasion, tend not to be
total hospital costs feJI 29%. Other
predictive,'' Dr. Burke said. "It's the
histologic diagnosis that is important." cost savings realized included decreases in laboratory costs of74%
Patients whose histology indicates
and
medication costs of 20%.
low risk but whose disease has
Postoperative
follow-up has also
invaded the wall of the uterus or
been
studied
by
the
gynecologic
extended into the cervix also require
oncology
group
at
M.
D. Anderson
more extensive staging procedures.
and
resulted
in
a
five-year
surveilRisk of recurrence and need of
lance follow-up schedule that can
postoperative treatment are also
determined from findings al surgery. be individualized by histologic
diag11osis.
In these paticni:s, Dr. Burke says,
Palients who require special
"there is a significant probability
monitoring other than those with
Lhat surgical staging can ckLect
variam cell types include those who
microscopic tumor elsewhere" and
have had cancer of the breast, ovary,
that the paLient will m:ed a very well
and colon. "Women who have had
laid plan of treatment after surgery.
one of these four cancers are at a
Postoperative therapy is Lypically
statistically higher risk of developing
radiation or chemotherapy, according to Dr. Burke, who said "how
one of the others ," he said.
uch-and-w-ha-t-k�Ad-i'5-FcaHy-i-aa·
Among--tJ1ose,w0me.R-whe takV1.dualizcd." Physicians at M. D .
tamoxifcn to prevent bi-east cancer
Anderson choose adjuva!'lt therapy
recurrence arc of special interest.
from institutional protocols and
However, incidence is low-only one
others that are part of national
or two per thousand women wh -o take
initiatives of the Gynecology
tamoxjfen are diagnosed with endomcOncology Group or tl1e Radiation
trial cancer-according to Dr. Burke,
Therapy Oncology Croup.
and risk has been related to the length
"Jf the patient has tumor outside
of time a patient is on the drug.
o f the uterus," Dr. Burke said, "the
'The current recommendation is
decision to take additional treatment that women who are candidates for
beyond surgery is a relatively easy
tamoxifen the rapy should take it only
one. We choose radiaLion, chemofor about £ve years," he said, "and
therapy, or hormonal therapy,
then discontinue it if they are free
depending on the reatures of the
of breast cancer." •
tumor and the location of the spread.
FOR MORE INFORMATION about eru.lornetrial
The real! )' diflicult call is the patient
who has no tumor detected outside
wncer treatment, contact Dr. 8'Urke at
the uterus but has high-risk features." (713) 792-2772.
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Endometrial Cancer
Variant Cell Types:
Two Cases

//T

his was a shock w me," said
the 64-year-old mother of
four grown children undergoing her third week of
postoperative adjuvant radiotherapy
(see CASE 1). With no record of
cancer in her medical history or
that of her family, learning she had
endometrial cancer was a surprise.
"We have diabetes and heart disease
in my family, but not cancer," she said.
The woman, who lives in Houston,
was diagnosed last summer with mixed
clear cell and uterine papillary serous
carcinoma of the endometrium,
variant cell types rJ1at along with
invasion into the cervix and a right
pelvic lymph node made her a candidate for whole abdominal adjuvant
postoperative radiation therapy.
About a month earlier, an 81-vearold Northeast Texas great�randmother, who had had a mastectomy
four years earlier and had been
taking tamoxifen, chose M. D.
Anderson from Lhe list of options her

Trials Offer Treatment
Options for Patients
with Endometrial
C-ance�

11

Clinical trials currently in progress at
The University of Texas M. D. Anderson
Ganeer Center include the following in
endometrial cancer.
• A randomized study of doxorubicin
plus cisplatin versus doxorubicin plus
24-hour paclitaxel plus granulocyte
colony-stimulating factor in patients
with primary stage Ill and IV or recurrent endometrial carcinoma (GOG 163).
Physician: Thomas W. Burke, M.D.
This study is conducted by the
Gynecologic Oncology Group. Patients
undergo treatment wtth either doxorubi-
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